PACran® Reduces UTIs

CARVER, Mass., and NUREMBERG, GermanyDaily supplementation of 500 mg of PACran® proanthocyanidin-standardized cranberry powder was twice as effective as placebo in reducing recurrent urinary tract infection (UTI), according to a new study presented at the 15^th annual PhytoPharm Congress 2011 in Nuremberg, Germany July 25 through 27, 2011. PACran from Decas Botanical Synergies LLC, can be added to dietary supplements and functional foods.

The six-month intervention trial assessed the efficacy of a daily dose of 500 mg of PACran® in women with a history of recurrent UTIs. The results showed 22 recurrent UTIs in the placebo group with 11 recurrent UTIs in the cranberry group. The recurrence rate for the cranberry group was 14.2 percent, corresponding to an absolute reduction in UTI recurrence of 15 percent. While the recurrence rate for the placebo group was 25.7 percent, corresponding to an assumed 30-percent recurrence rate in the placebo group.

According to Rahul Shinde, research scientist for Decas Botanical Synergie, this is thesecond clinical trial to show positive results for PACrans support for women with urinary health issues.

Dan Souza, senior director of sales and marketing, Decas Botanical Synergies, added In January 2011, the Federal Trade Commission (FTC) defined the health claim substantiation standard for structure function claims as at least two adequate and well-controlled human clinical studies of the product. The latest PACran study, coupled with previously published clinical results, give PACran the competent and reliable scientific evidence necessary to substantiate a cranberry-based urinary tract health structure function claim."

PACran is made from cranberries, and its patented formula provides superior potency at a substantially lower cost per dose, according to the company. In December 2009,  FDA approved a health claim for PACran and urinary health.